An Open-label Positron Emission Tomography Study to Investigate and Quantify Brain and Tumour Penetration of [11C]Lapatinib in Subjects With HER2-overexpressing Breast Cancer.
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2013
At a glance
- Drugs Lapatinib (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer; Brain metastases
- Focus Pharmacokinetics
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 May 2013 Planned end date changed from 1 Dec 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
- 05 Oct 2012 Planned end date changed from 1 Aug 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov record.